drugset / Trial / NCT02564107
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The anticipated time on study treatment is 25 weeks, and the target sample size is 50 individuals.
Timeline
- Start
- 2004-11
- Primary completion
- 2006-04
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibandronate | Other / unclassified | 50 mg | Oral |